Managers

Veteran Silicon Valley venture capital firm raises $1.5 billion fund: Reuters

Silicon Valley venture capital firm IVP on Tuesday announced the close of a $1.5 billion fund, the latest in a string of massive new venture funds that are appearing as global investors scramble for a piece of the tech boom.

Dynamk Capital collects capital for early-stage life sciences fund

Dynamk Capital has raised an undisclosed amount of capital in the first close of its early-stage venture fund focused on life sciences companies that provide tools, technologies and services. The fund is expected to close next year and will invest in eight to 10 companies.

Eligo Bioscience reels in $20 mln Series A

Paris-based Eligo Bioscience, a microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured $20 million in Series A financing. The investors included Khosla Ventures and Seventure Partners.

VC-backed Eloxx Pharmaceuticals names CFO

Israel and Waltham, Massachusetts-based Eloxx Pharmaceuticals Ltd, a developer of treatments that focus on genetic diseases caused by nonsense mutations, has appointed Gregory Weaver as chief financial officer. He is the former CFO at Prometic Life Sciences. The investors included Korea Investment Partners, DSC Investments, Pontifax Venture Capital and Quark Venture.

VC-backed Teckro taps Poff as COO

Ireland and New York City-based Teckro, a life sciences tech company, has hired Dana Poff as chief operating officer. Previously, she worked at ICON where she held senior roles in clinical operations, project management and alliance management. Teckro's backers include Sands Capital Ventures, Section 32 and Founders Fund.

IVP raises $1.5 bln for its largest ever fund; expects more AI, cryptocurrency deals

Deep Genomics lands $16 mln in follow-on round led by Khosla

Deep Genomics, a Toronto genetic medicine startup, has raised about $16 million (US$13 million) in follow-on financing. U.S. venture capital firm Khosla Ventures led the round and was joined by True Ventures, which led the company's $5 million seed financing in 2015. Spun out of the University of Toronto in 2014, Deep Genomics is building a biologically accurate, data- and artificial intelligence-driven technology platform that supports geneticists, molecular biologists and chemists in the development of therapies. It will use its platform to unlock new classes of anti-sense oligonucleotide therapies and advance them for clinical evaluation. Deep Genomics is led by CEO Brendan Frey.

Correlation's Coats headlines upcoming PC West event in Half Moon Bay

Sowing the seeds of Silicon Valley innovation in farm country

S2G Ventures collects $180 mln for second fund

Chicago-based S2G Ventures has raised $180 million for its second fund. Fund II will focus on the food and agriculture sector. Also, the firm has named Aaron Rudberg as managing director and chief operating officer.